Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.

Research in the field of inflammatory diseases has become one of the hottest areas of drug development, spurred on by an interest in novel therapies that have the potential to be more precise and more ...

Europe’s pandemic preparedness capital is creating a rare opening for biotech innovators. Since COVID-19, the next pandemic is no longer abstract, and preparedness is no longer optional. Europe is ...

Unlike traditional drugs that bind directly to a protein’s active site, allosteric modulators act at separate regulatory sites, allowing them to fine-tune biological activity and act more like a ...

Life science companies regularly forge mergers and acquisition (M&A) deals to eliminate competition or to expand a pipeline. Recently, there has been a spike in M&As, but analysts point towards ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...

The J.P. Morgan Healthcare Summit (JPM) serves as the world’s largest healthcare conference where healthcare professionals, scientists, and innovators meet with investors to set the agenda for the ...

The biopharma industry has seen its fair share of clinical and financial failures. When biotechs face setbacks, their stock values plummet and they lack the funds to develop new medicines, restructure ...

Hemophilia is a rare, genetic disorder in which the blood does not clot enough to make bleeding slow down or stop. This is because patients with hemophilia do not have the normal amount of clotting ...

News & press releases monitoring: We closely monitor the latest news and press releases, ensuring we only feature investments that could have a real impact on the industry. Specialized databases: We ...